Top Health Care companies in China by Cash and Short-Term Investments

This ranking features the top 412 Health Care companies in China ranked by Cash and Short-Term Investments, totaling a Cash and Short-Term Investments of USD 138.80 B, for June 17, 2025.

#	Name	Market Capitalization Share Price Year-To-Date (YTD) return Price to Earnings Ratio (P/E) Revenue EBIT EBITDA Net Income Free Cash Flow Dividend Yield Free Cash Flow Yield Total Assets Total Liabilities	Stock Price	Change	Price (30 days)	52W low/high	Sector

Items per page

1 2 3 4 … 9

Frequently Asked Questions

Which Health Care company in China has the highest Cash and Short-Term Investments ?

The Health Care company in China with the highest Cash and Short-Term Investments is Sinopharm Group Co. Ltd. (HKSE: 1099.HK) at USD 7.44 B.
Which Health Care company in China has the lowest Cash and Short-Term Investments ?

The Health Care company in China with the lowest Cash and Short-Term Investments is Golden Throat Holdings Group Company Limited (HKSE: 6896.HK) at None.

What are the top 10 Health Care companies in China by Cash and Short-Term Investments ?

The top 10 Health Care companies in China by Cash and Short-Term Investments are Sinopharm Group Co. Ltd., JD Health International Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Jiangsu Hengrui Medicine Co., Ltd., Hansoh Pharmaceutical Group Company Limited, WuXi AppTec Co., Ltd., Intco Medical Technology Co., Ltd., Jointown Pharmaceutical Group Co., Ltd, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited and Shenzhen Mindray Bio-Medical Electronics Co., Ltd..
What are the bottom 10 Health Care companies in China by Cash and Short-Term Investments ?

The bottom 10 Health Care companies in China by Cash and Short-Term Investments are Golden Throat Holdings Group Company Limited, Zhaoke Ophthalmology Limited, Wuhan YZY Biopharma Co Ltd, Genertec Universal Medical Group Company Limited, TOT BIOPHARM International Company Limited, JW (Cayman) Therapeutics Co. Ltd, ImmuneOnco Biopharmaceuticals (Shanghai) Inc., Cutia Therapeutics, Abbisko Cayman Limited and Ziyuanyuan Holdings Group Limited.